A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1, 3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease

European Journal of Pharmacology

Volumn 685, Issue 1-3, 2012, Pages 59-69

  Harada, Katsuya ^a   Nakato, Kazuhiro ^a   Yarimizu, Junko ^a   Yamazaki, Mayako ^a   Morita, Masahiko ^a   Takahashi, Shinji ^a   Aota, Masaki ^a   Saita, Kyoko ^a   Doihara, Hitoshi ^a   Sato, Yuichiro ^a   Yamaji, Takayuki ^a   Ni, Keni ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Alzheimer's disease; Animal model; Cognitive impairment; Glycine transporter; N methyl d aspartate (NMDA); Schizophrenia

Indexed keywords

4 [3 ISOPROPYL 5 (6 PHENYL 3 PYRIDYL) 4H 1,2,4 TRIAZOL 4 YL] 2,1,3 BENZOXADIAZOLE; ASP 2535; CLOZAPINE; DONEPEZIL; GLYCINE; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 2; HALOPERIDOL; PROTEIN INHIBITOR; SARCOSINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; LEARNING DISORDER; MALE; MEMBRANE PERMEABILITY; MEMORY DISORDER; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; VISUAL MEMORY; WORKING MEMORY;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MEMORY DISORDERS; MICE; OXADIAZOLES; PERMEABILITY; RATS; RATS, WISTAR; SCHIZOPHRENIA; TRIAZOLES;

EID: 84861339892     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.04.013     Document Type: Article

References (51)

1. Z. Abdul-Monim, G.P. Reynolds, and J.C. Neill The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm Behav. Brain Res. 169 2006 263 273
2. C. Aragón, and B. López-Corcuera Structure, function and regulation of glycine neurotransporters Eur. J. Pharmacol. 479 2003 249 262
3. R. Bergeron, T.M. Meyer, J.T. Coyle, and R.W. Greene Modulation of N-methyl-d-aspartate receptor function by glycine transport Proc. Natl. Acad. Sci. U. S. A. 95 1998 15730 15734
4. D.L. Braff, M.A. Geyer, and N.R. Swerdlow Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies Psychopharmacology (Berl) 156 2001 234 258
5. R.W. Buchanan, A. Breier, B. Kirkpatrick, P. Ball, and W.T. Carpenter Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome Arch. Gen. Psychiatry 155 1998 751 760
6. R.W. Buchanan, D.C. Javitt, S.R. Marder, N.R. Schooler, J.M. Gold, R.P. McMahon, U. Heresco-Levy, and W.T. Carpenter The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments Arch. Gen. Psychiatry 164 2007 1593 1602
7. J.X. Cai, and A.F.T. Arnsten Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys J. Pharmacol. Exp. Ther. 283 1997 183 189
8. D.H. Cheng, H. Ren, and X.C. Tang Huperzine A, a novel promising acetylcholinesterase inhibitor Neuroreport 8 1996 97 101
9. R. Cools, and M. D'Esposito Inverted-U-shaped dopamine actions on human working memory and cognitive control Biol. Psychiatry 69 2011 e113 e125
10. R. Depoortere, G. Dargazanli, G. Estenne-Bouhtou, A. Coste, C. Lanneau, C. Desvignes, M. Poncelet, M. Heaulme, V. Santucci, M. Decobert, A. Cudennec, C. Voltz, D. Boulay, J. Paul Terranova, J. Stemmelin, P. Roger, B. Marabout, M. Sevrin, X. Vige, B. Biton, R. Steinberg, D. Francon, R. Alonso, P. Avenet, F. Oury-Donat, G. Perrault, G. Griebel, P. George, P. Soubrie, and B. Scatton Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic Neuropsychopharmacology 30 2005 1963 1985
11. A. Ennaceur, and J. Delacour A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data Behav Brain Res. 31 1988 47 59
12. M.A. Geyer, K. Krebs-Thomson, D.L. Braff, and N.R. Swerdlow Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review Psychopharmacology (Berl) 156 2001 117 154
13. J.M. Gold Cognitive deficits as treatment targets in schizophrenia Schizophr. Res. 72 2004 21 28
14. J. Gomeza, F. Zafra, L. Olivares, C. Giménez, and C. Aragón Regulation by phorbol esters of the glycine transporter (GLYT1) in glioblastoma cells Biochimica et Biophysica Acta (BBA) - Biomembranes 1233 1995 41 46
15. J.T. Greenamyre, J.B. Penney, C.J. D'Amato, and A.B. Young Dementia of the Alzheimer's type: changes in hippocampal L-[3H]glutamate binding J. Neurochem. 48 1987 543 551
16. H. Hanyu, Y. Tanaka, H. Sakurai, M. Takasaki, and K. Abe Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease Neurosci. Lett. 319 2002 33 36
17. L.G. Harsing Jr., I. Gacsalyi, G. Szabo, E. Schmidt, N. Sziray, C. Sebban, B. Tesolin-Decros, P. Matyus, A. Egyed, M. Spedding, and G. Levay The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study Pharmacol. Biochem. Behav. 74 2003 811 825
18. K. Hashimoto Glycine transporter-1: a new potential therapeutic target for schizophrenia Curr. Pharm. Des. 17 2011 112 120
19. K. Hashimoto, Y. Fujita, E. Shimizu, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol Eur. J. Pharmacol. 519 2005 114 117
20. D.K. Ingram, E.D. London, and C.L. Goodrick Age and neurochemical correlates of radial maze performance in rats Neurobiol. Aging 2 1981 41 47
21. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Arch. Gen. Psychiatry 148 1991 1301 1308
22. R.S.E. Keefe, R.M. Bilder, S.M. Davis, P.D. Harvey, B.W. Palmer, J.M. Gold, H.Y. Meltzer, M.F. Green, G. Capuano, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, C.E. Davis, J.K. Hsiao, J.A. Lieberman for the, C.I., the Neurocognitive Working, G Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial Arch. Gen. Psychiatry 64 2007 633 647
23. R.S. Keefe, A.K. Malhotra, H.Y. Meltzer, J.M. Kane, R.W. Buchanan, A. Murthy, M. Sovel, C. Li, and R. Goldman Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial Neuropsychopharmacology 33 2008 1217 1228
24. J.A. Kemp, and P.D. Leeson The glycine site of the NMDA receptor - five years on Trends Pharmacol. Sci. 14 1993 20 25
25. G.G. Kinney, C. Sur, M. Burno, P.J. Mallorga, J.B. Williams, D.J. Figueroa, M. Wittmann, W. Lemaire, and P.J. Conn The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl] sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior J. Neurosci. 23 2003 7586 7591
26. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr., and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen Psychiatry 51 1994 199 214
27. P. Kubanis, and S.F. Zornetzer Age-related behavioral and neurobiological changes: a review with an emphasis on memory Behav. Neural Biol. 31 1981 115 172
28. M. Liem-Moolenaar, R.W.M. Zoethout, P. de Boer, M. Schmidt, M.L. de Kam, A.F. Cohen, K.L. Franson, and J.M.A. van Gerven The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects J. Psychopharmacol. (Oxf) 24 2010 1681 1687
29. M. Liem-Moolenaar, R.W.M. Zoethout, P. de Boer, M. Schmidt, M.L. de Kam, A.F. Cohen, K.L. Franson, and J.M.A. van Gerven The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects J. Psychopharmacol. (Oxf). 24 2010 1671 1679
30. A.S. Lippa, R.W. Pelham, B. Beer, D.J. Critchett, R.L. Dean, and R.T. Bartus Brain cholinergic dysfunction and memory in aged rats Neurobiol. Aging 1 1980 13 19
31. N. Matsuoka, and T.G. Aigner D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-d-aspartate receptors, improves visual recognition memory in rhesus monkeys J. Pharmacol. Exp. Ther. 278 1996 891 897
32. T. Maurice, and A. Privat SA4503, a novel cognitive enhancer with [sigma]1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice Eur. J. Pharmacol. 328 1997 9 18
33. S.L. McLean, J.P. Beck, M.L. Woolley, and J.C. Neill A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats Behav. Brain Res. 189 2008 152 158
34. H.Y. Meltzer, and S.R. McGurk The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophr. Bull. 25 1999 233 256
35. A.L. Mishara, and T.E. Goldberg A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book Biol. Psychiatry 55 2004 1013 1022
36. R.G. Morris Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-d-aspartate receptor antagonist AP5 J. Neurosci. 9 1989 3040 3057
37. T. Myhrer, T.S. Johannesen, and E. Spikkerud Restoration of mnemonic function in rats with glutamergic temporal systems disrupted: dose and time of glycine injections Pharmacol. Biochem. Behav. 45 1993 519 525
38. K.H. Nuechterlein, D.M. Barch, J.M. Gold, T.E. Goldberg, M.F. Green, and R.K. Heaton Identification of separable cognitive factors in schizophrenia Schizophr. Res. 72 2004 29 39
39. M. Ohno, and S. Watanabe D-Cycloserine, a glycine site agonist, reverses working memory failure by hippocampal muscarinic receptor blockade in rats Eur. J. Pharmacol. 318 1996 267 271
40. J. Parada-Turska, and W.A. Turski Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks Neuropharmacology 29 1990 1111 1116
41. G. Riedel, B. Platt, and J. Micheau Glutamate receptor function in learning and memory Behav. Brain Res. 140 2003 1 47
42. K. Rutten, J.D. Vente, A. Sik, M.M.-V. Ittersum, J. Prickaerts, and A. Blokland The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices Behav. Brain Res. 164 2005 11 16
43. M. Sarter, G. Bodewitz, and D.N. Stephens Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist beta-carbolines Psychopharmacology (Berl) 94 1988 491 495
44. A. ŞIk, P. van Nieuwehuyzen, J. Prickaerts, and A. Blokland Performance of different mouse strains in an object recognition task Behav. Brain Res. 147 2003 49 54
45. T. Tobe, T. Sugane, W. Hamaguchi, I. Shimada, K. Maeno, J. Miyata, T. Kimizuka, T. Suzuki, A. Kohara, T. Morita, M. Arlt, and H. Greiner Triazole derivatives. EP1293503 2003
46. G.E. Tsai, and P.-Y. Lin Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis Curr. Pharm. Des. 16 2010 522 537
47. G.E. Tsai, H.-Y. Lane, P. Yang, M.-Y. Chong, and N. Lange Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 55 2004 452 456
48. Z.P. Wang, S.Y. Man, and F. Tang Age-related changes in the contents of neuropeptides in the rat brain and pituitary Neurobiol. Aging 14 1993 529 534
49. C. Wang, J. McInnis, M. Ross-Sanchez, P. Shinnick-Gallagher, J.L. Wiley, and K.M. Johnson Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia Neuroscience 107 2001 535 550
50. M. Yamazaki, N. Matsuoka, N. Maeda, K. Kuratani, Y. Ohkubo, and I. Yamaguchi FR121196, a potential antidementia drug, ameliorates the impaired memory of rat in the Morris water maze J. Pharmacol. Exp. Ther. 272 1995 256 263
51. W.Q. Zhang, W.R. Mundy, L. Thai, P.M. Hudson, M. Gallagher, H.A. Tilson, and J.S. Hong Decreased glutamate release correlates with elevated dynorphin content in the hippocampus of aged rats with spatial learning deficits Hippocampus 1 1991 391 397